Incannex, a clinical-stage pharmaceutical company, agreed to acquire APIRx, a pharmaceutical company, for $93m. "We believe that bringing together Incannex and APIRx will bolster our position as a leader in the medicinal cannabinoid sector and will further set IHL apart from other players in the industry. With sizeable addressable markets and intellectual property spanning a multitude of unmet medical needs, we're positioning Incannex to be a significant player in the pharmaceutical sectors of the future. I'm excited by this acquisition opportunity on multiple fronts and look forward to working with the APIRx team to deliver on our vision of providing treatments which will make genuine differences to the lives of millions of people," Joel Latham, Incannex Managing Director and CEO.